Gemphire Therapeutics, which is developing a novel nonstatin therapy to treat high cholesterol, raised $30 million by offering 3 million shares at $10, below the range of $11 to $13. Gemphire Therapeutics plans to list on the Nasdaq under the symbol GEMP. Jefferies and RBC Capital Markets acted as lead managers on the deal.
